UTHR
Undervalued by 39.4% based on the discounted cash flow analysis.
Market cap | $12.07 Billion |
---|---|
Enterprise Value | $9.97 Billion |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $21.13 |
Beta | 0.32 |
Outstanding Shares | 44,355,694 |
Avg 30 Day Volume | 573,898 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 11.49 |
---|---|
PEG | 42.15 |
Price to Sales | 4.9 |
Price to Book Ratio | 2.29 |
Enterprise Value to Revenue | 3.99 |
Enterprise Value to EBIT | 7.93 |
Enterprise Value to Net Income | 9 |
Total Debt to Enterprise | 0.06 |
Debt to Equity | 0.11 |
No data
No data
United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power o...